TEV-56278 + pembrolizumab

**TEV-56278 + pembrolizumab** is an investigational combination therapy for advanced and metastatic solid tumors, currently in Phase 1 clinical development. TEV-56278 is an anti-PD-1 antibody–interleukin-2 (IL-2) fusion protein (ATTENUKINE) designed to selectively deliver IL-2 cytokine stimulation specifically to PD-1–expressing T cells within the tumor microenvironment, thereby amplifying anti-tumor immune responses while reducing systemic toxicity[1][4][8]. Pembrolizumab, marketed as Keytruda, is a monoclonal antibody PD-1 inhibitor approved in numerous cancers; when combined, the therapeutics aim to synergistically activate and sustain T-cell mediated anti-tumor activity[6]. The combination is being developed by Teva and Fosun Pharma for cancers including melanoma and other solid tumors, with documented activities of tumor regression, enhanced T-cell infiltration, and durable immune memory in preclinical and early clinical studies[1][4][6][8].

Other names

pembrolizumab